About
This forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.
The programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.
Publications
Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis
Publications
Abatacept in Individuals at High Risk of Rheumatoid Arthritis (APIPPRA): A Randomised, Double-blind, Multicentre, Parallel, Placebo-controlled, Phase 2b Clinical Trial
Publications
Long term safety of ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: A post hoc analysis of final safety data from 25 randomized clinical trials
Publications
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
Publications
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis
Publications
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Publications
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
Publications
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, Phase 3 trial
Publications
Efficacy of Baricitinib in Patients with Moderate-To-Severe Rheumatoid Arthritis up to 6.5 Years of Treatment: Results of a Long-Term Study
Publications
Continued JAK Inhibitor Treatment on the Risk of Recurrent Herpes Zoster Reactivation in Patients with Immune-mediated Inflammatory Diseases: A Nationwide Population-based Study in South Korea
Publications
Effectiveness and Safety of Filgotinib in Rheumatoid Arthritis: A Real-life Multicentre Experience
Publications
The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof‑of‑concept, open, prospective, clinical study
Publications
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the Phase 3 POETYK trials
Publications
Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-Year results from two Phase 3 studies
Publications
Effects of disease‑modifying anti‑rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: A systematic review and meta‑analysis
Podcasts
Discussing AxSpA: Bimekizumab in AxSpA & Secukinumab Patient Clustering
Podcasts
Discussing PsA: Impact of Biological Sex on Advanced Therapies & Upadacitinib-related Malignancies
Podcasts
AxSpA Podcast: Bimekizumab in AxSpA & Secukinumab Patient Clustering
Publications
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Publications
Sex-related Differences in Patient Characteristics, and Efficacy and Safety of Advanced Therapies in Randomised Clinical Trials in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
Publications
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two Phase 3 randomized trials in plaque psoriasis
Podcasts
Discussing AxSpA: Safety and Efficacy of Tofacitinib and Bimekizumab
Podcasts
Discussing PsA: Gender differences in treating PsA & safety of guselkumab in treating PsO and PsA
Podcasts
Discussing Rheumatology: November 2023
Breaking News
ACR 2023 - CSF coverage highlights the most relevant data on RA, PsA, and axSpA. Including our Preview Brochures highlighting key posters and oral presentations ahead of the congress.
Podcasts
Discussing PsA: Bimekizumab in treating bDMARD-naïve PsA & upadacitinib in treating csDMARD and bDMARD IR PsA
Publications
Long-term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
Podcasts
CSF Author Interview: Dr. David Martin, 2023
Podcasts
AxSpA Podcast: Safety and Efficacy of Upadacitinib
Publications
Effects of 1-year Tofacitinib Therapy on Angiogenic Biomarkers in Rheumatoid Arthritis
Publications
Global, Regional, and National Burden of Other Musculoskeletal Disorders, 1990–2020, and Projections to 2050: A Systematic Analysis of the Global Burden of Disease Study 2021
Podcasts